Industry News

Biotechnology Industry News

After a failed merger that led to…

September 17th, 2026|FierceBiotech|

After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with cardio specialist Marea Therapeutics.

Roche is paying Dualitas…

September 17th, 2026|FierceBiotech|

Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.

SK Biopharmaceuticals has added a…

September 17th, 2026|FierceBiotech|

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.

A phase 2b study of Longeveron’s…

September 17th, 2026|FierceBiotech|

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.

Senator Todd Young (R-IN),…

September 16th, 2026|FierceBiotech|

Senator Todd Young (R-IN), chairman of the National Security Commission on Emerging Biotechnology, told Fierce why he's concerned about the growth of China's biopharma industry.

Novo’s race to rejuvenate its…

September 16th, 2026|FierceBiotech|

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.

Novartis is paying Sironax $125…

September 16th, 2026|FierceBiotech|

Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.

Sling Therapeutics has closed a…

September 15th, 2026|FierceBiotech|

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.

After teasing a new initiative to…

September 15th, 2026|FierceBiotech|

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new drug (IND) application process that the agency hopes will

Connect Biopharma’s hopes of…

September 15th, 2026|FierceBiotech|

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.

Eli Lilly’s ongoing attempt to…

September 15th, 2026|FierceBiotech|

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.

GSK has bet up to $750 million on…

September 15th, 2026|FierceBiotech|

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The deal comes two

Novo’s attempted rebrand got off…

September 15th, 2026|FierceBiotech|

Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less

A phase 2 trial of Johnson &…

September 15th, 2026|FierceBiotech|

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.

As the FDA marches toward the…

September 14th, 2026|FierceBiotech|

As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously studied in the

Axoltis Pharma’s phase 2 trial for…

September 14th, 2026|FierceBiotech|

Axoltis Pharma's phase 2 trial for amyotrophic lateral sclerosis may have missed its primary endpoint, but the French biotech has pointed to secondary endpoints to justify persevering with the synthetic peptide.